糖尿病神经性疼痛市场－全球产业规模、份额、趋势、机会和预测，按神经病变类型、药物类别、配销通路、地区和竞争情况细分，2020 年至 2030 年

2024 年全球糖尿病神经性疼痛市场价值为 16.4 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 5.68%。全球糖尿病神经性疼痛市场是更广泛的医疗保健产业中一个充满活力且快速发展的产业，其特点是全球糖尿病盛行率不断上升。例如，2022 年国际糖尿病联盟报告称，全球约有 5.37 亿 20 至 79 岁的成年人患有糖尿病，占全球人口的十分之一，凸显了该疾病在全球范围内日益加重的负担。糖尿病神经性疼痛是糖尿病的一种痛苦和衰弱的併发症，影响着相当一部分糖尿病患者。该市场涵盖广泛的药物、医疗设备和治疗干预措施，旨在缓解糖尿病神经病变患者所经历的慢性疼痛和不适。推动全球糖尿病神经性疼痛市场成长的关键因素包括糖尿病发生率的上升，特别是在新兴经济体，以及全球人口老化。随着糖尿病的发生率不断上升，糖尿病神经病变的盛行率也在上升，这通常会导致神经性疼痛。这反过来又刺激了对有效疼痛管理解决方案的需求并推动了市场创新。例如，根据疾病预防控制中心的数据，美国约有 3,420 万人（占总人口的 10.5%）患有糖尿病，包括确诊和未确诊病例。相当一部分患者未被诊断出来或处于糖尿病前期，凸显了人们对糖尿病管理和预防日益增长的关注。

主要市场驱动因素

糖尿病疫情不断升级

主要市场挑战

治疗抵抗

主要市场趋势

以病人为中心的护理

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第 4 章：全球糖尿病神经性疼痛市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依神经病变类型（週边神经病变、自主神经病变、近端神经病变、局部神经病变）
  • 依药物类别（抗忧郁药、抗惊厥药、止痛药）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按神经病变类型
  • 按药物类别
  • 按配销通路
  • 按地区

第五章：亚太地区糖尿病神经性疼痛市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按神经病变类型
  • 按药物类别
  • 按配销通路
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 6 章：欧洲糖尿病神经性疼痛市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美糖尿病神经性疼痛市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲糖尿病神经性疼痛市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第九章：中东和非洲糖尿病神经性疼痛市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球糖尿病神经性疼痛市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Eli Lilly and Company
• Grunenthal GmBH
• Collegium Pharmaceutical, Inc.
• Lupin Ltd
• Daiichi Sankyo Inc.
• Azurity Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• Endo International plc. (Par Pharmaceutical)
• Johnson & Johnson

第 15 章：策略建议

第16章调查会社について・免责事项

Global Diabetic Neuropathic Pain Market was valued at USD 1.64 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.68% through 2030. The Global Diabetic Neuropathic Pain Market is a dynamic and rapidly evolving sector within the broader healthcare industry, characterized by a growing prevalence of diabetes worldwide. For instance, in 2022, the International Diabetes Federation reported that approximately 537 million adults aged 20 to 79 had diabetes, affecting 1 in 10 individuals worldwide, highlighting the growing global burden of the disease. Diabetic neuropathic pain is a distressing and debilitating complication of diabetes mellitus, affecting a significant proportion of diabetic patients. This market encompasses a wide range of pharmaceuticals, medical devices, and therapeutic interventions aimed at alleviating the chronic pain and discomfort experienced by individuals with diabetic neuropathy.Key factors driving the growth of the Global Diabetic Neuropathic Pain Market include the escalating incidence of diabetes, particularly in emerging economies, as well as the aging global population. As diabetes continues to rise, so does the prevalence of diabetic neuropathy, which often leads to neuropathic pain. This, in turn, fuels the demand for effective pain management solutions and drives innovation in the market. For instance, according to the CDC, around 34.2 million people in the U.S., or 10.5% of the population, have diabetes, including both diagnosed and undiagnosed cases. A substantial number remain undiagnosed or have prediabetes, highlighting the growing concern of diabetes management and prevention.

Key Market Drivers

Escalating Diabetes Epidemic

The escalating diabetes epidemic is undeniably one of the most potent drivers behind the growth of the Global Diabetic Neuropathic Pain Market. Diabetes has reached pandemic proportions, affecting millions of individuals worldwide, and its prevalence continues to surge at an alarming rate.This unprecedented rise in diabetes cases translates directly into a larger pool of individuals at risk of developing diabetic neuropathy, a debilitating complication that frequently leads to neuropathic pain. According to the Ministry of Health and Family Welfare, in collaboration with the WHO Country Office for India and other partners, launched mDiabetes, a mobile health initiative to raise awareness about early diabetes diagnosis and treatment. Similarly, WHO and IDF are working globally to prevent and control diabetes. The WHO Diabetes Program focuses on preventing type 2 diabetes, minimizing complications, and enhancing the quality of life for individuals with diabetes, reinforcing global efforts to improve diabetes care and management.

Key Market Challenges

Treatment Resistance

One of the primary reasons behind treatment resistance is the heterogeneous nature of diabetic neuropathic pain. The condition varies in terms of severity, duration, and underlying mechanisms among individuals. As a result, what works effectively for one patient may not provide the same level of relief for another. This variability underscores the need for personalized treatment approaches tailored to the specific characteristics of each patient's neuropathic pain.

Another contributing factor to treatment resistance is the limited efficacy of current pharmaceutical therapies. While these medications can provide relief for some patients, a significant portion of individuals with diabetic neuropathic pain continues to experience chronic and often debilitating discomfort. This treatment gap highlights the urgent need for more effective and targeted treatment options that can address the multifaceted nature of neuropathic pain.

Key Market Trends

Patient-Centered Care

Patient-centered care is a pivotal trend that is significantly boosting the Global Diabetic Neuropathic Pain Market. In the past, healthcare decisions often followed a one-size-fits-all approach, but the recognition of the unique needs and preferences of individual patients has led to a paradigm shift in the management of diabetic neuropathic pain. This patient-centric approach places the patient at the center of their care, involving them actively in decision-making processes, and tailoring treatment strategies to meet their specific needs.

Key Market Players

Eli Lilly and Company

Grunenthal GmBH

Collegium Pharmaceutical, Inc.

Lupin Ltd

Daiichi Sankyo Inc.

Azurity Pharmaceuticals, Inc.

Novartis AG

Pfizer, Inc.

Endo International plc. (Par Pharmaceutical)

Johnson & Johnson

Report Scope:

In this report, the Global Diabetic Neuropathic Pain Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Neuropathic Pain Market, By Neuropathy Type:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Diabetic Neuropathic Pain Market, By Drug Class:

• Antidepressants
• Anticonvulsants
• Analgesics

Diabetic Neuropathic Pain Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Neuropathic Pain Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Neuropathic Pain Market.

Available Customizations:

Global Diabetic Neuropathic Pain Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Neuropathic Pain Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Neuropathy Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy)
  • 4.2.2. By Drug Class (Antidepressants, Anticonvulsants, Analgesics)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Neuropathy Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Diabetic Neuropathic Pain Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Neuropathy Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Neuropathic Pain Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Neuropathy Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Diabetic Neuropathic Pain Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Neuropathy Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Diabetic Neuropathic Pain Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Neuropathy Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Diabetic Neuropathic Pain Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Neuropathy Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Diabetic Neuropathic Pain Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Neuropathy Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Distribution Channel

6. Europe Diabetic Neuropathic Pain Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Neuropathy Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Neuropathic Pain Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Neuropathy Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Diabetic Neuropathic Pain Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Neuropathy Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Diabetic Neuropathic Pain Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Neuropathy Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Diabetic Neuropathic Pain Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Neuropathy Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Diabetic Neuropathic Pain Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Neuropathy Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Distribution Channel

7. North America Diabetic Neuropathic Pain Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Neuropathy Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Neuropathic Pain Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Neuropathy Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Diabetic Neuropathic Pain Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Neuropathy Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Diabetic Neuropathic Pain Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Neuropathy Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel

8. South America Diabetic Neuropathic Pain Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Neuropathy Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Neuropathic Pain Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Neuropathy Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Diabetic Neuropathic Pain Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Neuropathy Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Diabetic Neuropathic Pain Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Neuropathy Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Diabetic Neuropathic Pain Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Neuropathy Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Neuropathic Pain Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Neuropathy Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Diabetic Neuropathic Pain Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Neuropathy Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Diabetic Neuropathic Pain Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Neuropathy Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. Egypt Diabetic Neuropathic Pain Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Neuropathy Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Neuropathic Pain Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Grunenthal GmBH
• 14.3. Collegium Pharmaceutical, Inc.
• 14.4. Lupin Ltd
• 14.5. Daiichi Sankyo Inc.
• 14.6. Azurity Pharmaceuticals, Inc.
• 14.7. Novartis AG
• 14.8. Pfizer, Inc.
• 14.9. Endo International plc. (Par Pharmaceutical)
• 14.10.Johnson & Johnson

15. Strategic Recommendations

16. About Us & Disclaimer